Wen Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wen Yang has a total of 228 co-authors. Here are the top co-authors by number of shared publications:
- Hongyang Wang
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
20 shared publications - Yingjie Xu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
17 shared publications Guishuai Lv
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
12 shared publicationsHongwei Lv
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
8 shared publicationsJie Wang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publicationsLiang Wang
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
6 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Disrupting the NAD+/NAM metabolic ratio driven by IL-1β inflammatory response potentiates chemotherapy and chemoimmunotherapy in mice
Nicotinamide adenine dinucleotide (NAD+) replenishment sensitizes tumors to immunotherapy. However, chemotherapy-induced NAD+ metabolic reprogramming remains poorly understood. Here, we show that chemotherapy induces a macrophage-dependent IL-1β inflammatory response and NAD+ metabolic reprogramming, thereby conferring chemoresistance via CD44. Mechanistically, IL-1β-induced NAD+ salvage cooperates with the clearance of nicotinamide (NAM), the physiological inhibitor of the NAD+-consuming enzymes sirtuins, to drive CD44-mediated chemoresistance by boosting the NAD+/NAM ratio for sirtuin activation. NAM phosphoribosyltransferase (NAMPT)-mediated NAD+ salvage recycles NAD+ from NAM and further triggers serine biosynthesis, ultimately supporting NAM N-methyltransferase (NNMT)-mediated NAM clearance. Importantly, NAMPT inhibition disrupts the NAD+/NAM ratio and mitigates CD44-mediated chemoresistance and NK cell dysfunction, ultimately enhancing the efficacy of chemoimmunotherapy when combined with IL-2 across multiple preclinical models of solid tumors. Thus, our findings underscore the NAD+/NAM ratio as a metabolic therapeutic target for enhancing chemotherapy and NK cell-based chemoimmunotherapy efficacy.
- 13 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDisrupting the NAD+/NAM metabolic ratio driven by IL-1β inflammatory response potentiates chemotherapy and chemoimmunotherapy in mice
Nicotinamide adenine dinucleotide (NAD+) replenishment sensitizes tumors to immunotherapy. However, chemotherapy-induced NAD+ metabolic reprogramming remains poorly understood. Here, we show that chemotherapy induces a macrophage-dependent IL-1β inflammatory response and NAD+ metabolic reprogramming, thereby conferring chemoresistance via CD44. Mechanistically, IL-1β-induced NAD+ salvage cooperates with the clearance of nicotinamide (NAM), the physiological inhibitor of the NAD+-consuming enzymes sirtuins, to drive CD44-mediated chemoresistance by boosting the NAD+/NAM ratio for sirtuin activation. NAM phosphoribosyltransferase (NAMPT)-mediated NAD+ salvage recycles NAD+ from NAM and further triggers serine biosynthesis, ultimately supporting NAM N-methyltransferase (NNMT)-mediated NAM clearance. Importantly, NAMPT inhibition disrupts the NAD+/NAM ratio and mitigates CD44-mediated chemoresistance and NK cell dysfunction, ultimately enhancing the efficacy of chemoimmunotherapy when combined with IL-2 across multiple preclinical models of solid tumors. Thus, our findings underscore the NAD+/NAM ratio as a metabolic therapeutic target for enhancing chemotherapy and NK cell-based chemoimmunotherapy efficacy.
- Open Access
- 24 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 148
miR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway
Autophagy is controlled by a complex signalling network and is closely linked to the initiation and progression of hepatocellular carcinoma (HCC). However, how microRNAs (miRNAs) regulate autophagy in HCC remains incompletely understood. In this study, we identified microRNA-486-5p (miR-486-5p) as a tumour-associated microRNA that is enriched in circulating exosomes derived from patients with HCC. Elevated miR-486-5p promoted proliferation and suppressed apoptosis in HCC cell lines under stress conditions. Mechanistically, miR-486-5p directly targets the 3′ untranslated region of the phosphatase and tensin homologue ( PTEN ) gene, thereby decreasing the production of the PTEN protein and consequently leading to the activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway. This phenomenon was accompanied by the inhibitory phosphorylation of unc-51 like autophagy-activating kinase 1 (ULK1), which resulted in impaired autophagy. The pharmacological inhibition of AKT or mTOR led to the restoration of autophagy and the attenuation of miR-486-5p-driven growth and survival advantages. Furthermore, the transcription factor MYB was found to bind the promoter of ankyrin-1 ( ANK1 ), the host gene of miR-486-5p, and to drive its expression. In an orthotopic liver tumour model, the liver-targeted delivery of miR-486-5p accelerated tumour expansion, an effect that was reversed by AKT or mTOR blockade. Collectively, these findings delineate a MYB/miR-486-5p/PTEN/AKT/mTOR signalling axis that constrains autophagy to facilitate HCC progression, suggesting potential avenues for biomarker development and therapeutic intervention.
- 24 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 148
Open AccessmiR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway
Autophagy is controlled by a complex signalling network and is closely linked to the initiation and progression of hepatocellular carcinoma (HCC). However, how microRNAs (miRNAs) regulate autophagy in HCC remains incompletely understood. In this study, we identified microRNA-486-5p (miR-486-5p) as a tumour-associated microRNA that is enriched in circulating exosomes derived from patients with HCC. Elevated miR-486-5p promoted proliferation and suppressed apoptosis in HCC cell lines under stress conditions. Mechanistically, miR-486-5p directly targets the 3′ untranslated region of the phosphatase and tensin homologue ( PTEN ) gene, thereby decreasing the production of the PTEN protein and consequently leading to the activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway. This phenomenon was accompanied by the inhibitory phosphorylation of unc-51 like autophagy-activating kinase 1 (ULK1), which resulted in impaired autophagy. The pharmacological inhibition of AKT or mTOR led to the restoration of autophagy and the attenuation of miR-486-5p-driven growth and survival advantages. Furthermore, the transcription factor MYB was found to bind the promoter of ankyrin-1 ( ANK1 ), the host gene of miR-486-5p, and to drive its expression. In an orthotopic liver tumour model, the liver-targeted delivery of miR-486-5p accelerated tumour expansion, an effect that was reversed by AKT or mTOR blockade. Collectively, these findings delineate a MYB/miR-486-5p/PTEN/AKT/mTOR signalling axis that constrains autophagy to facilitate HCC progression, suggesting potential avenues for biomarker development and therapeutic intervention.
- 7 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218720
Tertiary lymphoid structures and hepatocellular carcinoma: Guardian and executioner
- 7 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218720
Tertiary lymphoid structures and hepatocellular carcinoma: Guardian and executioner
- Open Access
- 16 December 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00813
Deep learning analysis of urine-derived stem cell mitochondrial morphology as a non-invasive Alzheimer’s disease biomarker
- 16 December 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00813
Open AccessDeep learning analysis of urine-derived stem cell mitochondrial morphology as a non-invasive Alzheimer’s disease biomarker
- 15 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 202
Revisiting ROS: duality in organ aging progression
The functions of multiple organs decline with the process of aging. Revealing the intrinsic mechanisms governing organ degeneration is a critical pursuit for understanding the aging process and creating interventions for aging-related diseases. Macromolecular damage caused by the generation of reactive oxygen species (ROS) increases with the process of aging. However, excessive ROS generation may only partially account for aging at the individual and organ levels. In contrast, they could serve as important signaling molecules in stress responses. In this review, we focused on the dual role of ROS in the aging processes of several human organ systems. Through this investigation, we aim to reassess the relationship between ROS and aging.
- 15 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 202
Revisiting ROS: duality in organ aging progression
The functions of multiple organs decline with the process of aging. Revealing the intrinsic mechanisms governing organ degeneration is a critical pursuit for understanding the aging process and creating interventions for aging-related diseases. Macromolecular damage caused by the generation of reactive oxygen species (ROS) increases with the process of aging. However, excessive ROS generation may only partially account for aging at the individual and organ levels. In contrast, they could serve as important signaling molecules in stress responses. In this review, we focused on the dual role of ROS in the aging processes of several human organ systems. Through this investigation, we aim to reassess the relationship between ROS and aging.
- 10 August 2025
- Published by Elsevier in Cancer Letters
- Vol. 636, 217978
LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma
- 10 August 2025
- Published by Elsevier in Cancer Letters
- Vol. 636, 217978
LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma
- Open Access
- 7 August 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-18
Investigating the shared genetic information between serum concentration levels of liver enzymes and cholelithiasis
Liver injury is associated with cholelithiasis, with changes in liver enzyme levels potentially influencing cholelithiasis risk. This study investigates the shared genetic basis between serum levels of four liver enzymes and cholelithiasis using summary data from large-scale genome-wide association studies (GWAS). We assessed genetic correlation between liver enzymes and cholelithiasis, and performed local genetic correlation analysis to identify shared genomic regions. A cross-trait meta-analysis identified significant SNPs (single nucleotide polymorphisms) shared between the enzymes and cholelithiasis. To explore causal effects, we applied both two-sample Mendelian randomization and multivariable Mendelian randomization. Heritability-based enrichment analysis was employed to identify tissues and cells jointly associated with liver enzymes and cholelithiasis, while summary-data-based Mendelian Randomization (SMR) was utilized to identify shared genes. Alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) showed relatively stronger genetic correlations with cholelithiasis compared to the other liver enzymes. Shared SNPs were identified among ALT, GGT, alkaline phosphatase (ALP), and cholelithiasis. Mendelian randomization indicated that a tenfold increase in ALT could raise cholelithiasis risk by 203.4%. The liver was identified as the primary tissue linking these enzymes to cholelithiasis, but no shared cell types were implicated. Several candidate genes, such as SPTLC3, may jointly influence liver enzyme levels and cholelithiasis risk. Elevated ALT levels may increase cholelithiasis risk. Genetic associations across tissues, genes, and SNPs suggest that liver enzymes could mediate the relationship between liver injury and cholelithiasis risk, providing insights into shared genetic mechanisms with potential implications for future research.
- 7 August 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-18
Open AccessInvestigating the shared genetic information between serum concentration levels of liver enzymes and cholelithiasis
Liver injury is associated with cholelithiasis, with changes in liver enzyme levels potentially influencing cholelithiasis risk. This study investigates the shared genetic basis between serum levels of four liver enzymes and cholelithiasis using summary data from large-scale genome-wide association studies (GWAS). We assessed genetic correlation between liver enzymes and cholelithiasis, and performed local genetic correlation analysis to identify shared genomic regions. A cross-trait meta-analysis identified significant SNPs (single nucleotide polymorphisms) shared between the enzymes and cholelithiasis. To explore causal effects, we applied both two-sample Mendelian randomization and multivariable Mendelian randomization. Heritability-based enrichment analysis was employed to identify tissues and cells jointly associated with liver enzymes and cholelithiasis, while summary-data-based Mendelian Randomization (SMR) was utilized to identify shared genes. Alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) showed relatively stronger genetic correlations with cholelithiasis compared to the other liver enzymes. Shared SNPs were identified among ALT, GGT, alkaline phosphatase (ALP), and cholelithiasis. Mendelian randomization indicated that a tenfold increase in ALT could raise cholelithiasis risk by 203.4%. The liver was identified as the primary tissue linking these enzymes to cholelithiasis, but no shared cell types were implicated. Several candidate genes, such as SPTLC3, may jointly influence liver enzyme levels and cholelithiasis risk. Elevated ALT levels may increase cholelithiasis risk. Genetic associations across tissues, genes, and SNPs suggest that liver enzymes could mediate the relationship between liver injury and cholelithiasis risk, providing insights into shared genetic mechanisms with potential implications for future research.
- Open Access
- 3 July 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
FL3 mitigates cardiac ischemia-reperfusion injury by promoting mitochondrial fusion to restore calcium homeostasis
This study aims to investigate the therapeutic potential of Flavagline3 (FL3) in mitigating myocardial ischemia-reperfusion (IR) injury, with a specific focus on its regulatory effects on mitochondrial fusion, mitochondrial-endoplasmic reticulum (ER) interactions, and calcium homeostasis in cardiomyocytes. Using a well-established myocardial IR injury model in mice and primary cardiomyocytes treated with FL3, the study assessed its impact on mitochondrial dynamics and intracellular signaling processes. The results demonstrated that FL3 effectively reduced myocardial apoptosis, infarct size, and cardiac dysfunction caused by IR injury. Mechanistically, FL3 promoted mitochondrial fusion in a mitofusin1 (MFN1)-dependent manner, preserving mitochondrial function under stress conditions and enhancing cellular resilience. Furthermore, FL3 facilitated mitochondrial-ER crosstalk, which played a critical role in modulating intracellular calcium levels by optimizing the transfer of calcium ions between these two organelles. This balanced regulation of mitochondrial dynamics and calcium homeostasis was associated with improved survival and functionality of cardiomyocytes following IR injury. These findings suggest that FL3 exerts robust cardioprotective effects through its ability to promote mitochondrial fusion, enhance mitochondrial-ER interactions, and maintain calcium homeostasis. As a result, FL3 holds promise as a potential therapeutic agent for reducing myocardial damage and dysfunction associated with IR injury, offering valuable insights into novel approaches for cardioprotection.
- 3 July 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Open AccessFL3 mitigates cardiac ischemia-reperfusion injury by promoting mitochondrial fusion to restore calcium homeostasis
This study aims to investigate the therapeutic potential of Flavagline3 (FL3) in mitigating myocardial ischemia-reperfusion (IR) injury, with a specific focus on its regulatory effects on mitochondrial fusion, mitochondrial-endoplasmic reticulum (ER) interactions, and calcium homeostasis in cardiomyocytes. Using a well-established myocardial IR injury model in mice and primary cardiomyocytes treated with FL3, the study assessed its impact on mitochondrial dynamics and intracellular signaling processes. The results demonstrated that FL3 effectively reduced myocardial apoptosis, infarct size, and cardiac dysfunction caused by IR injury. Mechanistically, FL3 promoted mitochondrial fusion in a mitofusin1 (MFN1)-dependent manner, preserving mitochondrial function under stress conditions and enhancing cellular resilience. Furthermore, FL3 facilitated mitochondrial-ER crosstalk, which played a critical role in modulating intracellular calcium levels by optimizing the transfer of calcium ions between these two organelles. This balanced regulation of mitochondrial dynamics and calcium homeostasis was associated with improved survival and functionality of cardiomyocytes following IR injury. These findings suggest that FL3 exerts robust cardioprotective effects through its ability to promote mitochondrial fusion, enhance mitochondrial-ER interactions, and maintain calcium homeostasis. As a result, FL3 holds promise as a potential therapeutic agent for reducing myocardial damage and dysfunction associated with IR injury, offering valuable insights into novel approaches for cardioprotection.
- Open Access
- 27 April 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (6) , 2832-2845
Multi-omics Analysis Sheds Light on the Extracellular Role of PCMT1
Proteins are constantly damaged by intracellular and extracellular factors, particularly under stress conditions, leading to an accumulation of modified proteins such as isoaspartate (isoD), which is linked to aging and various diseases. The repair enzyme PCMT1 (protein-l-isoaspartate o-methyltransferase) specifically restores isoD residues to aspartate, preventing abnormal protein functions. Despite its importance, its role in non-neural tissues remains underexplored. This study employed isoD-proteomics, global proteomics, and transcriptomics on Pcmt1 knockout (KO) and wild-type (WT) mice, revealing significant gene and protein changes in various KO tissues, enriched in extracellular and membrane-related categories, highlighting genome-proteome correlations. IsoD-carrying proteins were increased in KO tissues, predominantly consisting of long-lived proteins. Additionally, the proteomic analysis of PCMT1-overexpressing cells identified interacting proteins mainly in extracellular and membrane-related categories. These findings revealed both tissue-specific and shared roles of PCMT1, emphasizing its importance in maintaining protein integrity under physiological and stress conditions while also uncovering an unexpected extracellular function of PCMT1.
- 27 April 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (6) , 2832-2845
Open AccessMulti-omics Analysis Sheds Light on the Extracellular Role of PCMT1
Proteins are constantly damaged by intracellular and extracellular factors, particularly under stress conditions, leading to an accumulation of modified proteins such as isoaspartate (isoD), which is linked to aging and various diseases. The repair enzyme PCMT1 (protein-l-isoaspartate o-methyltransferase) specifically restores isoD residues to aspartate, preventing abnormal protein functions. Despite its importance, its role in non-neural tissues remains underexplored. This study employed isoD-proteomics, global proteomics, and transcriptomics on Pcmt1 knockout (KO) and wild-type (WT) mice, revealing significant gene and protein changes in various KO tissues, enriched in extracellular and membrane-related categories, highlighting genome-proteome correlations. IsoD-carrying proteins were increased in KO tissues, predominantly consisting of long-lived proteins. Additionally, the proteomic analysis of PCMT1-overexpressing cells identified interacting proteins mainly in extracellular and membrane-related categories. These findings revealed both tissue-specific and shared roles of PCMT1, emphasizing its importance in maintaining protein integrity under physiological and stress conditions while also uncovering an unexpected extracellular function of PCMT1.
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Repair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Open AccessRepair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.